nified Trans diagnostic Treatment
Not Applicable
Recruiting
- Conditions
- Premenstrual syndrome.Premenstrual tension syndromeN94.3
- Registration Number
- IRCT20201128049518N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Diagnosis of premenstrual syndrome based on diagnostic and Statistical Manual of Mental Disorders (DSM)
Lack of mental retardation
No use of psychiatric drugs before the study
Exclusion Criteria
Dissatisfaction to participate in study
Psychiatric comorbidity
Drug allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptoms of Premenstrual. Timepoint: At the first of study (before the intervention), 4 and 8 week after starting psychotherapy sessions in experimental and control group premenstrual symptoms are evaluated. Method of measurement: Premenstrual Syndrome Screening (PSST).;Quality of sleep. Timepoint: At the first of study (before the intervention), 4 and 8 week after starting psychotherapy sessions in experimental and control group quality of sleep is evaluated. Method of measurement: Iowa Sleep Disturbances Inventory (ISDI).;????? ?????? ?????. Timepoint: At the first of study (before the intervention), 4 and 8 week after starting psychotherapy sessions in experimental and control group cognitive emotion regulation is evaluated. Method of measurement: Cognitive Emotion Regulation Questionnaire (CERQ).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link emotion regulation to premenstrual syndrome (PMS) symptom remission in IRCT20201128049518N1?
How does Unified Transdiagnostic Treatment compare to SSRIs or hormonal therapies for PMS-related sleep disturbances?
Which neuroendocrine biomarkers (e.g., cortisol, melatonin) predict response to transdiagnostic cognitive interventions in PMS?
What adverse events are associated with transdiagnostic psychological therapies for PMS, and how are they managed?
Are there pharmacological combinations (e.g., SSRIs + melatonin agonists) that synergize with Unified Transdiagnostic Treatment for PMS?